EFFECTS OF THE BET-INHIBITOR APABETALONE ON CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND ACUTE CORONARY SYNDROME, ACCORDING TO PRESENCE OR ABSENCE OF CHRONIC KIDNEY DISEASE. A BETONMACE TRIAL REPORT

被引：0
|
作者：
Kalantar-Zadeh, Kam [1 ]
Ray, Kausik K. [2 ]
Nicholls, Stephen J. [3 ]
Ginsburg, Henry N. [4 ]
Buhr, Kevin A. [5 ]
Johansson, Jan [6 ]
Kulikowski, Ewelina [7 ]
Toth, Peter P. [8 ]
Sweeney, Michael [6 ]
Schwartz, Gregory G. [9 ]
机构：
[1] Univ Calif Irvine, Div Nephrol & Hypertens, Irvine, CA USA
[2] Imperial Coll, Imperial Ctr Cardiovasc Dis Prevent, London, England
[3] Monash Univ, MonashHeart, Melbourne, Vic, Australia
[4] Columbia Univ, New York, NY USA
[5] Univ Wisconsin, Stat Data Anal Ctr, Madison, WI USA
[6] Resverlogix Corp, San Francisco, CA USA
[7] Resverlogix Corp, Res, Calgary, AB, Canada
[8] Univ Illinois, Coll Med, Dept Family & Community Med, Peoria, IL 61656 USA
[9] VA Denver Aurora, Div Cardiol, Aurora, CO USA
来源：
NEPHROLOGY DIALYSIS TRANSPLANTATION | 2020年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R3 [基础医学]; R4 [临床医学];
学科分类号：
1001 ; 1002 ; 100602 ;
摘要：
TO001
引用
收藏
页码：182 / 182
页数：1
相关论文
共 50 条
  • [1] APABETALONE REDUCES CARDIOVASCULAR EVENTS IN PATIENTS WITH CHRONIC KIDNEY DISEASE, TYPE 2 DIABETES, AND RECENT ACUTE CORONARY SYNDROME: A BETONMACE TRIAL REPORT
    Kalantar-Zadeh, Kamyar
    Nicholls, Stephen J.
    Buhr, Kevin A.
    Ginsburg, Henry N.
    Johansson, Jan
    Kulikowski, Ewelina
    Toth, Peter P.
    Wong, Norman
    Sweeney, Michael
    Schwartz, Gregory G.
    Ray, Kausik K.
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2020, 75 (05) : 819 - 819
  • [2] Reduction in the Risk of Major Adverse Cardiovascular Events With Apabetalone, a Bet Protein Inhibitor, in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes According to Insulin Treatment: Analysis of the Betonmace Trial
    Schwartz, Gregory G.
    Nicholls, Stephen J.
    Ginsberg, Henry
    Johansson, Jan
    Kalantar-Zadeh, Kamyar
    Kulikowski, Ewelina
    Toth, Peter P.
    Wong, Norman
    Sweeney, Michael
    Ray, Kausik K.
    CIRCULATION, 2020, 142
  • [3] THE EPIGENETIC BET-INHIBITOR APABETALONE REDUCES CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES, ACUTE CORONARY SYNDROME AND AN ELEVATED ANGULO NON-ALCOHOLIC FATTY LIVER DISEASE FIBROSIS SCORE - EXPLORATORY ANALYSIS OF THE BETONMACE TRIAL
    Toth, Peter P.
    Schwartz, Gregory G.
    Nicholls, Stephen J.
    Johansson, Jan
    Ginsberg, Henry
    Kalantar-Zadeh, Kamyar
    Kulikowski, Ewelina
    Wong, Norman C.
    Szarek, Michael
    Sweeney, Michael
    Ray, Kausik Kumar
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022, 79 (09) : 1104 - 1104
  • [4] Effect of BET Protein Inhibition With Apabetalone on Cardiovascular Outcomes in Patients With Acute Coronary Syndrome and Diabetes - Results of the BETonMACE Trial
    Ray, Kausik K.
    Nicholls, Stephen J.
    Ginsberg, Henry N.
    Johansson, Jan O.
    Kalantar-Zadeh, Kamyar
    Kulikowski, Ewelina
    Toth, Peter P.
    Wong, Norman
    Sweeney, Michael
    Schwartz, Gregory G.
    CIRCULATION, 2019, 140 (25) : E966 - E966
  • [5] Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial
    Ray, Kausik K.
    Nicholls, Stephen J.
    Ginsberg, Henry D.
    Johansson, Jan O.
    Kalantar-Zadeh, Kamyar
    Kulikowski, Ewelina
    Toth, Peter P.
    Wong, Norman
    Cummings, Jeffrey L.
    Sweeney, Michael
    Schwartz, Gregory G.
    AMERICAN HEART JOURNAL, 2019, 217 : 72 - 83
  • [6] THE BET PROTEIN INHIBITOR APABETALONE REDUCES CONGESTIVE HEART FAILURE INCIDENCE IN PATIENTS WITH ACUTE CORONARY SYNDROME AND DIABETES: RESULTS FROM THE BETONMACE TRIAL
    Sweeney, Michael
    Nicholls, Stephen J.
    Ray, Kausik Kumar
    Buhr, Kevin
    Ginsberg, Henry
    Johansson, Jan
    Kalantar-Zadeh, Kamyar
    Kulikowski, Ewelina
    Toth, Peter
    Wong, Norman
    Schwartz, Gregory G.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (11) : 168 - 168
  • [7] Apabetalone, a selective BET protein inhibitor, reduces ischemic cardiovascular events and hospitalization for heart failure in patients with acute coronary syndrome and type 2 diabetes
    Ray, K. K.
    Nicholls, S. J.
    Buhr, K. A.
    Ginsberg, H. N.
    Kalantar-Zadeh, K.
    Johansson, J. O.
    Kulikowski, E.
    Toth, P. P.
    Wong, N.
    Sweeney, M.
    Schwartz, G. G.
    EUROPEAN HEART JOURNAL, 2020, 41 : 1425 - 1425
  • [8] DESIGN FEATURES OF THE BETONMACE CHRONIC KIDNEY DISEASE SUB-STUDY; EFFECTS OF THE SELECTIVE BET-INHIBITOR APABETALONE ON KIDNEY FUNCTION AND MACE IN POST-ACS PATIENTS WITH ESTIMATED GLOMERULAR FILTRATION RATE BELOW 60 AND DIABETES
    Kalantar-Zadeh, Kam
    Johansson, Jan
    Kulikowski, Ewelina
    Halliday, Christopher
    Lebioda, Ken
    Sweeney, Mike
    Wong, Norman
    Nicholls, Stephen
    Schwartz, Gregory
    Ray, Kausik
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2018, 33
  • [9] Mild to moderate chronic kidney disease and cardiovascular events in patients with type 2 diabetes mellitus
    Lessey, Gayatri
    Stavropoulos, Konstantinos
    Papademetriou, Vasilios
    VASCULAR HEALTH AND RISK MANAGEMENT, 2019, 15 : 365 - 373
  • [10] Type 2 Diabetes and Chronic Kidney Disease as Predictors of Cardiovascular Events in Patients with Coronary Artery Disease
    Plattner, Thomas
    Larcher, Barbara
    Mader, Arthur
    Vonbank, Alexander
    Leiherer, Andreas
    Muendlein, Axel
    Drexel, Heinz
    Saely, Christoph H.
    DIABETES, 2024, 73
12345